2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/2iy5wruuedsh6.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/00yc7rcvua6a7.js","/_next/static/immutable/chunks/37ktb71aq3480.js","/_next/static/immutable/chunks/2d50b-7eu4558.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/2d6noqpp6ehas.js","/_next/static/immutable/chunks/1sx186c93bpzg.js","/_next/static/immutable/chunks/3dc-1n866s65i.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2w1bvggzb0ga8.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T669,Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment-seeking individuals with CUD. A phase 2, randomized, double-blind, parallel group, placebo-controlled trial was conducted. Two outpatient research clinics in South Carolina, USA, from February 2020 to February 2023. Eligible participants met Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for CUD and used cannabis a minimum of 3 days per week. One hundred and seventy-four participants were randomized to either varenicline (n = 90) or placebo (n = 84) stratified by smoking status and sex. Varenicline (titrated to goal dose of 1 mg twice daily) or matching placebo for 12 weeks. Medical management was provided weekly. Primary outcome measure was reduction in total number of cannabis use sessions at each weekly visit (weeks 6-12). There was no main effect of treatment on reduction of total number of cannabis use sessions per week during weeks 6 through 12 [between group difference (Δ) = 1.7; 95% confidence interval (CI) = -1.0 to 4.7; P = 0.41]; however, a statistically significant treatment by sex interaction was found (F Varenicline with medical management resulted in decreased cannabis use among men with cannabis use disorder seeking treatment, but not women (no effect was observed on the overall sample of treatment-seeking individuals with cannabis use disorder).31:Tf0e,Abstract Background and aims Although cannabis use is widespread and prevalence of cannabis use disorder (CUD) is increasing, limited advancements have been made in CUD medication development. The objective of this study was to test the efficacy of varenicline with medical management for reducing cannabis use in treatment‐seeking individuals with CUD. Design A phase 2, randomized, double‐blind, parallel group, placebo‐controlled trial was conducted. Setting Two outpatient research clinics in South Carolina, USA, from February 2020 to February 2023. Participants Eligible participants met Diagnostic and Statistical Manual of Mental Disorders , Fifth Edition (DSM‐5) criteria for CUD and used cannabis a minimum of 3 days per week. One hundred and seventy‐four participants were randomized to either varenicline ( n = 90) or placebo ( n = 84) stratified by smoking status and sex. Interventions Varenicline (titrated to goal dose of 1 mg twice daily) or matching placebo for 12 weeks. Medical management was provided weekly. Measurements Primary outcome measure was reduction in total number of cannabis use sessions at each weekly visit (weeks 6–12). Findings There was no main effect of treatment on reduction of total number of cannabis use sessions per week during weeks 6 through 12 [between group difference (Δ) = 1.7; 95% confidence interval (CI) = −1.0 to 4.7; P = 0.41]; however, a statistically significant treatment by sex interaction was found (F 1,132 = 5.1; P = 0.026), with a statistically significant effect of varenicline on reduction of cannabis use sessions per week observed in men (Δ = 4.2; 95% CI = 0.6–7.8; P = 0.04) but not women (Δ = −1.4; 95% CI = −5.7 to 3.0; P = 0.18). Conclusions Varenicline with medical management resulted in decreased cannabis use among men with cannabis use disorder seeking treatment, but not women (no effect was observed on the overall sample of treatment‐seeking individuals with cannabis use disorder). 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"varenicline: generic Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on varenicline (generic). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/generic/varenicline\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Generics\",\"item\":\"https://www.reachrx.ai/hub/tag/generic\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"varenicline\",\"item\":\"https://www.reachrx.ai/hub/tag/generic/varenicline\"}]}}"}}]],["$","$L2f",null,{"title":"varenicline: Research & Clinical Takeaways","description":"Explore research on varenicline (generic) — efficacy, safety, and comparative data.","papers":[{"doi":"10.1111/add.70296","pmid":"41536001","title":"Varenicline for cannabis use disorder: A randomized controlled trial","journal_title":"Addiction","journal_issn":"0965-2140","published_at":"2026-01-15T00:00:00.000Z","url":"https://doi.org/10.1111/add.70296","source_score":88,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-01-19","doi":"10.1111/add.70296","days":"14","issn":"0965-2140","rank":"10","field":"Clinical Medicine","score":"88","category":"Psychiatry","categories":["Psychiatry"],"_categories":["Psychiatry"]},"pubmed":{"doi":"10.1111/add.70296","title":"Varenicline for cannabis use disorder: A randomized controlled trial.","journal":"Addiction (Abingdon, England)","methods":"","results":"","abstract":"$30","keywords":["cannabis","cannabis use disorder","medical management","pharmacotherapy|","sex differences","varenicline"],"pubmed_id":"41536001","conclusions":"","publication_date":"2026-01-15T00:00:00"},"crossref":{"DOI":"10.1111/add.70296","URL":"https://doi.org/10.1111/add.70296","ISSN":["0965-2140","1360-0443"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/add.70296","content-type":"application/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https://onlinelibrary.wiley.com/doi/full-xml/10.1111/add.70296","content-type":"application/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/add.70296","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Varenicline for cannabis use disorder: A randomized controlled trial"],"author":[{"given":"Aimee L.","family":"McRae‐Clark","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences Medical University of South Carolina Charleston SC USA"},{"name":"Ralph H. Johnson VA Medical Center Charleston SC USA"}]},{"given":"Kevin M.","family":"Gray","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences Medical University of South Carolina Charleston SC USA"}]},{"given":"Nathaniel L.","family":"Baker","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences Medical University of South Carolina Charleston SC USA"}]},{"given":"Brian J.","family":"Sherman","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences Medical University of South Carolina Charleston SC USA"}]},{"given":"Bryan","family":"Tolliver","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences Medical University of South Carolina Charleston SC USA"}]},{"given":"Jessica","family":"Burt","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences Medical University of South Carolina Charleston SC USA"}]},{"given":"Alonzo","family":"Steplight","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences Medical University of South Carolina Charleston SC USA"}]},{"given":"Elizabeth","family":"Chapman","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences Medical University of South Carolina Charleston SC USA"}]},{"given":"Amanda","family":"Wagner","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences Medical University of South Carolina Charleston SC USA"}]}],"funder":[{"id":[{"id":"10.13039/100000002","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100000002","name":"National Institutes of Health","award":["UH3DA043231"],"award-info":[{"award-number":["UH3DA043231"]}],"doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2026,1,14]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":null,"archive":["Portico"],"created":{"date-time":"2026-01-15T05:01:09Z","timestamp":1768453269000,"date-parts":[[2026,1,15]]},"indexed":{"date-time":"2026-01-15T19:46:07Z","timestamp":1768506367509,"date-parts":[[2026,1,15]]},"license":[{"URL":"http://creativecommons.org/licenses/by-nc/4.0/","start":{"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000,"date-parts":[[2026,1,14]]},"delay-in-days":0,"content-version":"vor"},{"URL":"http://doi.wiley.com/10.1002/tdm_license_1.1","start":{"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000,"date-parts":[[2026,1,14]]},"delay-in-days":0,"content-version":"tdm"}],"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/add.70296"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-05-20"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-11-14"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2026-01-14"}],"deposited":{"date-time":"2026-01-15T05:01:14Z","timestamp":1768453274000,"date-parts":[[2026,1,15]]},"issn-type":[{"type":"print","value":"0965-2140"},{"type":"electronic","value":"1360-0443"}],"published":{"date-parts":[[2026,1,14]]},"publisher":"Wiley","reference":[{"DOI":null,"key":"e_1_2_10_2_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Substance Abuse and Mental Health Services Administration.Results from the 2022 National Survey on Drug Use and Health: Detailed tables. Accessed April 10 2024.https://www.samhsa.gov/data/report/2022-nsduh-detailed-tables","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1080/09540261.2018.1465398","key":"e_1_2_10_3_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.drugalcdep.2019.05.008","key":"e_1_2_10_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/phar.1747","key":"e_1_2_10_5_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1146/annurev.pharmtox.47.120505.105214","key":"e_1_2_10_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0306-4522(00)00371-7","key":"e_1_2_10_7_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1124/mol.106.025130","key":"e_1_2_10_8_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1503/cmaj.070256","key":"e_1_2_10_9_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.296.1.47","key":"e_1_2_10_10_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/jama.296.1.56","key":"e_1_2_10_11_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.euroneuro.2009.11.001","key":"e_1_2_10_12_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s00213-014-3518-1","key":"e_1_2_10_13_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.biopsych.2009.01.029","key":"e_1_2_10_14_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s00213-010-2160-9","key":"e_1_2_10_15_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s00213-012-2717-x","key":"e_1_2_10_16_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1097/ADM.0b013e31829623f4","key":"e_1_2_10_17_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_10_18_1","year":"2018","issue":null,"author":"O'Malley SS","volume":"75","first-page":"129","unstructured":null,"article-title":"Effect of varenicline combined with medical management on alcohol use disorder: a randomized clinical trial","journal-title":"JAMA","doi-asserted-by":null},{"DOI":"10.1016/j.phrs.2023.106746","key":"e_1_2_10_19_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.drugalcdep.2021.109111","key":"e_1_2_10_20_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_10_21_1","year":"1998","issue":"20","author":"Sheehan DV","volume":"59","first-page":"22","unstructured":null,"article-title":"The Mini‐international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM‐IV and ICD‐10","journal-title":"J Clin Psychiatry","doi-asserted-by":null},{"DOI":null,"key":"e_1_2_10_22_1","year":"1992","issue":null,"author":"Sobell LC","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/j.drugalcdep.2015.08.013","key":"e_1_2_10_23_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.drugalcdep.2017.04.020","key":"e_1_2_10_24_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.drugalcdep.2011.06.003","key":"e_1_2_10_25_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1046/j.1360-0443.2001.967102312.x","key":"e_1_2_10_26_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1176/appi.ajp.2011.10111704","key":"e_1_2_10_27_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_10_28_1","year":"2018","issue":null,"author":"Hay RD","volume":"27","first-page":"1185","unstructured":null,"article-title":"PROMIS‐29 v2.0 profile physical and mental health summary scores","journal-title":"Qual Life Res","doi-asserted-by":null},{"DOI":"10.1186/s13293-022-00441-3","key":"e_1_2_10_29_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/j.0006-341X.2001.00120.x","key":"e_1_2_10_30_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/ntr/ntv207","key":"e_1_2_10_31_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1037/0893-164X.21.2.216","key":"e_1_2_10_32_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0740-5472(00)00148-3","key":"e_1_2_10_33_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1037/0022-0167.45.3.265","key":"e_1_2_10_34_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1177/002204260903900310","key":"e_1_2_10_35_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1089/can.2016.0010","key":"e_1_2_10_36_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.drugalcdep.2020.107993","key":"e_1_2_10_37_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1176/appi.ajp.20230508","key":"e_1_2_10_38_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1176/appi.ajp.161.11.1967","key":"e_1_2_10_39_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/add.70296"],"article-number":"add.70296","content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Addiction"],"reference-count":38,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,1,14]]},"references-count":38,"short-container-title":["Addiction"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1111/add.70296","is_oa":true,"title":"Varenicline for cannabis use disorder: A randomized controlled trial","updated":"2026-01-17T01:14:18+00:00","published_date":"2026-01-14","best_oa_location":{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/add.70296","pmh_id":null,"url_for_pdf":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/add.70296","url_for_landing_page":"https://doi.org/10.1111/add.70296"}}},"created_at":"2026-01-21T12:05:26.220Z","updated_at":"2026-01-21T12:05:26.220Z","tags":[{"paper_doi":"10.1111/add.70296","tag_type":"category","value":"Psychiatry","value_numeric":null},{"paper_doi":"10.1111/add.70296","tag_type":"condition","value":"Cannabis Use Disorder","value_numeric":null},{"paper_doi":"10.1111/add.70296","tag_type":"generic","value":"varenicline","value_numeric":null},{"paper_doi":"10.1111/add.70296","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1111/add.70296","tag_type":"sample_size","value":"n=174","value_numeric":174},{"paper_doi":"10.1111/add.70296","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1111/add.70296","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1111/add.70296","tag_type":"warning","value":"Details of the treatment-by-sex interaction statistic are truncated in the provided text; exact values by sex were not reported here.","value_numeric":null},{"paper_doi":"10.1111/add.70296","tag_type":"warning","value":"Only the abstract was available; full methods, adherence, and adverse event data are not included.","value_numeric":null},{"paper_doi":"10.1111/add.70296","tag_type":"warning","value":"Participant age range was not reported in the abstract.","value_numeric":null}],"summaries":{"what_studied":"A phase 2, randomized, double-blind, placebo-controlled parallel-group trial at two outpatient clinics tested varenicline (titrated to 1 mg twice daily) plus weekly medical management versus placebo for 12 weeks in treatment-seeking individuals meeting DSM-5 criteria for cannabis use disorder (n=174; varenicline n=90, placebo n=84); the primary outcome was reduction in total cannabis use sessions at weekly visits during weeks 6–12.","key_result":"No overall treatment effect on cannabis use sessions during weeks 6–12 (between-group Δ=1.7 sessions/week; 95% CI −1.0 to 4.7; P=0.41); there was a statistically significant treatment-by-sex interaction with decreased use among men but not women.","limitations":"Conducted at two clinics in one U.S. state, which may limit generalizability; benefit was observed only in men despite no overall effect; outcomes were assessed over a 12-week treatment period (primary window weeks 6–12), capturing short-term change only.","practice_takeaway":"Do not expect varenicline plus medical management to reduce cannabis use across all adults with cannabis use disorder; any benefit appears limited to men, with no observed effect in women."}}],"initialOffset":1,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"generic","value":"varenicline"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Generics","href":"/hub/tag/generic"},{"name":"varenicline"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"generic","hub_tag_value":"varenicline"}}}]]

Papers